April 23, 2021 - First COVID-19 patients treated with COR-101 drug developed in Braunschweig.
CORAT Therapeutics GmbH announced the start of a clinical trial with COR-101 for treatment of COVID-19 in hospitalized patients. The novel therapeutic antibody may complement currently approved antibody drugs, which are not indicated for moderate to severe COVID-19 cases due to side effects during advanced stages of the disease.
March 29, 2021 - Braunschweig anti-cancer antibody in clinical trials in the USA: New Drug Grips Tumor Cells With Two Arms.
The first patients with advanced tumors have been treated with the novel antibody-based drug M1231 in a clinical trial in the USA. It uses an invention of the Technical University of Braunschweig: The team of Professor Stefan Dübel, head of the Department of Biotechnology, discovered a human antibody that targets tumor cells and developed it over many years. This antibody is now part of a complex novel compound against difficult-to-treat cancers that is undergoing clinical testing by the pharmaceutical company Merck.
In 2002, Prof. Dr. Stefan Dübel joined the Department as director, adding the new research focus on Molecular Engineering, in particular Human Antibody Engineering and Phage Display. The Department quickly became the home to some of the world's largest and most successful academic human monoclonal antibody libraries, while the well established research focus on Biochemical Engineering, led by Prof. Dr. Siegmund Lang and Prof. Dr. Udo Rau, continued its succesful development. A major current focus was developed by Prof. Dr. Michael Hust on the fight against infectious diseaseses.
Today, with fundamental and applied research topics spanning a very broad range including molecular and cell biology, infection biology, intrabodies, biomarker and drug discovery, vaccine development, synthetic biology and in vitro evolution, the Department is well-endowed to embark into the challenges of cutting egde biotechnology research of the future, with a clear focus to increase the quality of life for everybody.
A long list of successful technology transfers includes the successful developmet of clinical stage anti-cancer and anti-virus antibodies, and novel approaches to avoid animal experiments for antibody generation. Several spin-off biotech companies help to translate our discoveries into solutions for the benefit of all, and we will continue our efforts to pave new ways to develop designer drugs for the 21st century.
Department of Biotechnology Institute for Biochemistry, Biotechnology and Bioinformatics Technical University of Braunschweig
By train: For all railway connections, see Deutsche Bahn. Exit Braunschweig main station. Just in front, slightly left, are bus platforms. Take the bus line 419 (direction: Hauptbahnhof, leaves about every 10 min at workdays), exit at Gliesmaroder Straße (5th stop) or Bültenweg (6th stop) (klick map for larger version). Bus connection details: http://www.braunschweiger-verkehrs-ag.de
By air: Nearest airport with scheduled service is Hannover (HAJ). Best way of transfer to Braunschweig is to take an airport shuttle (45 min, needs reservation) or train (ca. 1,5 h, change of train at Hannover main station). In some cases, particular from overseas, it may be faster to fly into Frankfurt (FRA) and take the comfortable ICE train to Braunschweig (3,5 hours); most ICE connections are via Frankfurt main railway station. From Berlin's airports it takes about 2,5h by train or car - you may take a taxi to the Berlin main station and use the ICE train (1,3h) to Braunschweig. For all railway connections, see Deutsche Bahn.
For visitors using their own aircraft, Braunschweig-Wolfsburg airport (IATA: BWE, ICAO: EDVE) is located 7km (15 min by Taxi) from the Institute. There are no scheduled public passenger services. Position N52°19.16' E10°33.53' in 297ft MSL, TORA2300m, ILS RWY 26, NDB/RNAV RWY 08/26 TWR 120,055 MHz, NDB BRU 427 kHz (all informations not for navigation) METAR/TAF